SCHEMBL7140086

SCHEMBL7140086

CCOC(=O)CC(NC(=O)CNC(=O)c1nc(NC(=O)NCc2ccccc2)sc1C)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
ITGB3 P05106 1/20 0.46
ITGAV P06756 1/20 0.46
PPID Q08752 1/20 0.44
CSNK1D P48730 2/20 0.41
LCK P06239 2/20 0.41
ALDH1A1 P00352 3/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 3/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
SCD O00767 1/20 0.40
NAMPT P43490 1/20 0.39
KDM4E B2RXH2 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
TAOK1 Q7L7X3 1/20 0.38
TAOK3 Q9H2K8 1/20 0.38
SLC6A9 P48067 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7139106 0.91 ITGB3 (0.47) MEN1KMT2AITGB3ITGAVPPID
SCHEMBL7140143 0.91 ITGB3 (0.55) MEN1KMT2AITGB3ITGAVLCK
SCHEMBL7142342 0.86 ALDH1A1 (0.42) MEN1KMT2AITGB3CSNK1DALDH1A1
SCHEMBL27490978 0.80 ITGB1 (0.42) MEN1KMT2AITGB3ITGAVLCK
SCHEMBL7143700 0.80 ROCK2 (0.43) KMT2AITGB3ITGAVPPIDALDH1A1
SCHEMBL7145328 0.79 ITGB3 (0.59) MEN1KMT2AITGB3ITGAVLCK
SCHEMBL6773780 0.79 NAMPT (0.49) ITGB3ITGAVPPIDALDH1A1LMNA
SCHEMBL7138145 0.78 MAPT (0.41) MEN1KMT2AITGB3CSNK1DALDH1A1
SCHEMBL7145393 0.78 HIF1A (0.47) ALDH1A1LMNAMAPTRAB9ASMN1; SMN2
SCHEMBL7140430 0.77 ALDH1A1 (0.41) MEN1KMT2AITGB3CSNK1DALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6320054-B1 INHIBIT BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES F CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. HOFFMAN-LA ROCHE INC. 2001-11-20 US claimed
EP-0928790-B1 Thiazole derivatives HOFFMANN LA ROCHE (CH) 2003-03-05 EP disclosed
US-6344562-B1 ANTITUMOR AGENTS HOFFMANN-LA ROCHE INC. 2002-02-05 US disclosed
US-20020010316-A1 Thiazole derivatives ALIG LEO (CH) 2002-01-24 US disclosed
US-6320054-B1 INHIBIT BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES F CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. HOFFMAN-LA ROCHE INC. 2001-11-20 US disclosed
US-6100282-A Thiazole derivatives HOFFMAN-LA ROCHE INC. (US) 2000-08-08 US disclosed
EP-0928790-A1 Thiazole derivatives F. HOFFMANN-LA ROCHE AG (CH) 1999-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010316-A1 Thiazole derivatives VCAM1, SOST, TGFB1 MEN1 681/4885KMT2A 4510/4885ITGB3 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.